Hutchmed (HKG:0013) is weighing its supply chain options for blood cancer drug, tazemetostat, amid the impact of US tariffs against China, the South China Morning Post reported Monday, citing chief executive and scientific officer Su Weiguo.
China's medical products administrator in March approved tazemetostat for follicular-lymphoma patients with an EZH2 mutation and who have not responded to treatment or those who have recurrent cancer.
Because tazemetostat is currently made in the US, it could be subjected to tariffs should it be imported into China, the report said.
Should the impact of tariffs be substantial, Hutchmed may look to manufacture the anti-cancer drug in Europe or China, Su reportedly said.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.